Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding.
A simple two-marker blood test from vaginal fluid can detect endometrial cancer with 96% accuracy, potentially sparing some women from invasive procedures.
Researchers at Mayo Clinic optimized methylated DNA markers from 19 to a 2-marker panel for detecting endometrial cancer in self-collected vaginal fluid, achieving 96% sensitivity and 97% AUC in prospective validation. This non-invasive approach could replace or triage invasive endometrial sampling in patients presenting with abnormal uterine bleeding.
What the study was
- Study design
- Prospective marker optimization and independent validation study
- Population
- Women ≥45 years with abnormal uterine bleeding/postmenopausal bleeding, plus EC/AEH cases ≥18 years; self-collected vaginal fluid via tampon
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Gynecologic Oncology
Why it surfaced
Prospectively validated non-invasive endometrial cancer detection from self-collected vaginal fluid with 96% sensitivity and AUC 0.97; potentially practice-changing for reducing invasive biopsy in high-risk patients.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.